381. Comparative Effectiveness and Safety of Apixaban, Rivaroxaban, and Warfarin in Patients With Cirrhosis and Atrial Fibrillation : A Nationwide Cohort Study.
作者: Tracey G Simon.;Daniel E Singer.;Yichi Zhang.;Julianna M Mastrorilli.;Alexander Cervone.;Elyse DiCesare.;Kueiyu Joshua Lin.
来源: Ann Intern Med. 2024年177卷8期1028-1038页
Apixaban, rivaroxaban, and warfarin have shown benefit for preventing major ischemic events, albeit with increased bleeding risk, among patients in the general population with atrial fibrillation (AF). However, data are scarce in patients with cirrhosis and AF.
383. Medication-Induced Weight Change Across Common Antidepressant Treatments : A Target Trial Emulation Study.
作者: Joshua Petimar.;Jessica G Young.;Han Yu.;Sheryl L Rifas-Shiman.;Matthew F Daley.;William J Heerman.;David M Janicke.;W Schuyler Jones.;Kristina H Lewis.;Pi-I D Lin.;Carly Prentice.;John W Merriman.;Sengwee Toh.;Jason P Block.
来源: Ann Intern Med. 2024年177卷8期993-1003页
Antidepressants are among the most commonly prescribed medications, but evidence on comparative weight change for specific first-line treatments is limited.
384. Angiotensin-Converting Enzyme Inhibitors or Angiotensin-Receptor Blockers for Advanced Chronic Kidney Disease : A Systematic Review and Retrospective Individual Participant-Level Meta-analysis of Clinical Trials.
作者: Elaine Ku.;Lesley A Inker.;Hocine Tighiouart.;Charles E McCulloch.;Ogechi M Adingwupu.;Tom Greene.;Raymond O Estacio.;Mark Woodward.;Dick de Zeeuw.;Julia B Lewis.;Thierry Hannedouche.;Tazeen H Jafar.;Enyu Imai.;Giuseppe Remuzzi.;Hiddo J L Heerspink.;Fan Fan Hou.;Robert D Toto.;Philip K Li.;Mark J Sarnak.
来源: Ann Intern Med. 2024年177卷7期953-963页
In patients with advanced chronic kidney disease (CKD), the effects of initiating treatment with an angiotensin-converting enzyme inhibitor (ACEi) or angiotensin-receptor blocker (ARB) on the risk for kidney failure with replacement therapy (KFRT) and death remain unclear.
387. Lesbian, Gay, Bisexual, Transgender, Queer, and Other Sexual and Gender Minority Health Disparities: A Position Paper From the American College of Physicians.
Lesbian, gay, bisexual, transgender, queer, or other sexual and gender minorities (LGBTQ+) populations in the United States continue to experience disparities in health and health care. Discrimination in both health care and society at large negatively affects LGBTQ+ health. Although progress has been made in addressing health disparities and reducing social inequality for these populations, new challenges have emerged. There is a pressing need for physicians and other health professionals to take a stance against discriminatory policies as renewed federal and state public policy efforts increasingly impose medically unnecessary restrictions on the provision of gender-affirming care. In this position paper, the American College of Physicians (ACP) reaffirms and updates much of its long-standing policy on LGBTQ+ health to strongly support access to evidence-based, clinically indicated gender-affirming care and oppose political efforts to interfere in the patient-physician relationship. Furthermore, ACP opposes institutional and legal restrictions on undergraduate, graduate, and continuing medical education and training on gender-affirming care and LGBTQ+ health issues. This paper also offers policy recommendations to protect the right of all people to participate in public life free from discrimination on the basis of their gender identity or sexual orientation and encourages the deployment of inclusive, nondiscriminatory, and evidence-based blood donation policies for members of LGBTQ+ communities. Underlying these beliefs is a reaffirmed commitment to promoting equitable access to quality care for all people regardless of their sexual orientation and gender identity.
392. Attention Among Health Care Professionals : A Scoping Review.
作者: Mark J Kissler.;Samuel Porter.;Michelle Knees.;Katherine Kissler.;Angela Keniston.;Marisha Burden.
来源: Ann Intern Med. 2024年177卷7期941-952页
The concept of attention can provide insight into the needs of clinicians and how health systems design can impact patient care quality and medical errors.
393. Metformin Use in the First Trimester of Pregnancy and Risk for Nonlive Birth and Congenital Malformations: Emulating a Target Trial Using Real-World Data.
作者: Yu-Han Chiu.;Krista F Huybrechts.;Elisabetta Patorno.;Jennifer J Yland.;Carolyn E Cesta.;Brian T Bateman.;Ellen W Seely.;Miguel A Hernán.;Sonia Hernández-Díaz.
来源: Ann Intern Med. 2024年177卷7期862-870页
Metformin is a first-line pharmacotherapy for type 2 diabetes, but there is limited evidence about its safety in early pregnancy.
396. Paternal Use of Metformin During the Sperm Development Period Preceding Conception and Risk for Major Congenital Malformations in Newborns.
作者: Ran S Rotem.;Marc G Weisskopf.;Krista F Huybrechts.;Sonia Hernández-Díaz.
来源: Ann Intern Med. 2024年177卷7期851-861页
Metformin is the most used oral antidiabetic medication. Despite its established safety profile, it has known antiandrogenic and epigenetic modifying effects. This raised concerns about possible adverse developmental effects caused by genomic alterations related to paternal use of metformin during the spermatogenesis period preceding conception.
397. COVID-19 Vaccine Side Effects and Long-Term Neutralizing Antibody Response : A Prospective Cohort Study.
作者: Ethan G Dutcher.;Elissa S Epel.;Ashley E Mason.;Frederick M Hecht.;James E Robinson.;Stacy S Drury.;Aric A Prather.
来源: Ann Intern Med. 2024年177卷7期892-900页
Concern about side effects is a common reason for SARS-CoV-2 vaccine hesitancy.
400. Lifetime Health and Economic Outcomes of Biparametric Magnetic Resonance Imaging as First-Line Screening for Prostate Cancer : A Decision Model Analysis.
作者: Roman Gulati.;Boshen Jiao.;Ra'ad Al-Faouri.;Vidit Sharma.;Sumedh Kaul.;Aaron Fleishman.;Kevin Wymer.;Stephen A Boorjian.;Aria F Olumi.;Ruth Etzioni.;Boris Gershman.
来源: Ann Intern Med. 2024年177卷7期871-881页
Contemporary prostate cancer (PCa) screening uses first-line prostate-specific antigen (PSA) testing, possibly followed by multiparametric magnetic resonance imaging (mpMRI) for men with elevated PSA levels. First-line biparametric MRI (bpMRI) screening has been proposed as an alternative.
|